Sinopharm, Sinovac to apply for EUA in PH this week, says envoy | Global News

ÃÛÌÒ¹¤×÷ÊÒ

Sinopharm, Sinovac to apply for EUA in PH this week, says envoy

By: - Reporter /
/ 02:40 PM January 04, 2021

MANILA, Philippines — Chinese vaccine makers Sinopharm and Sinovac will apply for an emergency use authorization (EUA) in the Philippines’ Food and Drug Administration (FDA) this week, Manila’s envoy to Beijing Jose Santiago “Chito” Sto. Romana said Monday.

“Our embassy is in touch with these two companies, of course, and we try to facilitate their contact with IATF [Inter-Agency Task Force for the Management of Emerging Infectious Diseases] and if there’s any information that’s needed. We asked when they will file for EUA sa  (with) FDA sa Pilipinas (in the Philippines),” Sto. Romana said in an online Palace briefing.

Article continues after this advertisement

“Apparently, their plan right now, according to them, is that they hope to file in the next few days. Some time this week, they will file their EUA application with FDA in the Philippines,” he added.

FEATURED STORIES

. Its efficacy rate was reported to be at 79.34 percent.

Sinovac’s COVID-19 vaccine, which has a 50 percent efficacy, had earlier secured EUA from China.

Only American drugmaker .

KGA
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the and acknowledge that I have read the .

For more news about the novel coronavirus click

For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this

MOST READ
www
newsinfo
newsinfo
sports
newsinfo
www
TAGS: China, Coronavirus, COVID-19, COVID-19 vaccine, Health, pandemic, Philippines, SARS-CoV-2, sinopharm, sinovac, Vaccine, virus

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the and acknowledge that I have read the .

© Copyright 1997-2024 ÃÛÌÒ¹¤×÷ÊÒ | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies.